Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Hologic’s SEC reports can feel like reviewing an FDA submission—dense tables on Panther diagnostic assay margins, breast-health imaging upgrades, and goodwill adjustments from Gen-Probe. Add in complex risk factors on regulatory approvals and you have hundreds of pages that busy investors rarely finish. That’s why users search for “Hologic SEC filings explained simply� or “how to read a Hologic annual report 10-K.�
Stock Titan’s AI solves that problem. Our engine converts every Hologic annual report 10-K simplified, each Hologic quarterly earnings report 10-Q filing, and every Hologic 8-K material events explained into plain-language briefs, highlighting FDA milestones, segment revenue swings, and cash-flow drivers. Need real-time alerts? You’ll see Hologic Form 4 insider transactions real-time the moment executives file, plus side-by-side graphs of option grants and share repurchases. From Hologic proxy statement executive compensation details to the next Hologic earnings report filing analysis, every document is updated the second it hits EDGAR.
The result: faster, sharper decisions. Track Hologic insider trading Form 4 transactions to gauge management sentiment, compare operating margins across Diagnostics and Surgical segments without combing through footnotes, and monitor covenant disclosures before debt maturities surface. Whether you’re understanding Hologic SEC documents with AI for a quick thesis check or following Hologic executive stock transactions Form 4 ahead of product launches, Stock Titan gives you complete coverage, AI-powered summaries, and expert context—no more scrolling through 250 pages to find one number.
Hologic (HOLX) Q3 FY25 10-Q highlights: Revenue edged up 1.2% YoY to $1.024 bn, with U.S. sales flat and Europe +16% offsetting a 7% decline in Asia-Pac. Diagnostics grew 2% to $449 m and GYN Surgical +7% to $178 m, while Breast Health fell 5% to $365 m. Gross margin improved 100 bp to 56.4%, lifting operating income 4% to $254.6 m. Net income was stable at $194.9 m; diluted EPS rose 5% to $0.86 on a 5% lower share count.
Year-to-date revenue was flat at $3.05 bn, but $221 m of intangible impairments pushed net income down 38% to $378.5 m (EPS $1.66). Operating cash flow fell 24% to $702 m, while the company spent $753 m on share buybacks and $322 m on acquisitions, cutting cash to $1.74 bn (-$425 m since Sept-24). Debt remains ~ $2.5 bn; on 15 Jul 25 HOLX refinanced its credit facility, trimming the term loan to $1.17 bn and keeping a $1.25 bn revolver.
Balance-sheet leverage is modest (net cash > $-0.4 bn) and equity totals $4.84 bn. Remaining performance obligations stand at $898 m, 58% due within three years. Management continues portfolio pruning (SSI divestiture) and expansion (Gynesonics $341 m, Endomag $314 m) while absorbing restructuring costs ($17.6 m YTD).
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
